Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation

Jean El CheikhDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Correspondence[email protected]

Radwan MassoudDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;

Basel HaffarDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;

Elie FaresDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;

Rami MahfouzDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;

Tamima JisrDivision of Hematology and Oncology, Makassed University hospital, Beirut, Lebanon;

Mohamed A. Kharfan-DabajaDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL, USA

Anas MougharbelDivision of Hematology and Oncology, Makassed University hospital, Beirut, Lebanon;

Ali YoussefDivision of Hematology and Oncology, Makassed University hospital, Beirut, Lebanon;

Ali BazarbachiDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;

Ahmad IbrahimDivision of Hematology and Oncology, Makassed University hospital, Beirut, Lebanon;

show all

Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date